Top Page
AdAlta Ltd.
(Sydney:1AD)
AdAlta Ltd. (1AD) vs. S&P 500 (SPY)
AdAlta Ltd. Business Overview & Revenue Model
AdAlta Ltd. Financial Statement Overview
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 973.02K | 1.74M | 3.47M | 2.75M | 3.98M | 3.83M | Gross Profit |
| 761.18K | 1.51M | 3.44M | 2.49M | 3.78M | 3.66M | EBIT |
| -4.79M | -5.26M | -8.34M | -6.00M | -5.42M | -5.84M | EBITDA |
| -4.84M | -5.30M | -4.84M | -5.97M | -5.39M | -5.80M | Net Income Common Stockholders |
| -4.94M | -5.38M | -4.85M | -6.06M | -5.63M | -6.01M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 3.68M | 3.13M | 4.79M | 8.66M | 5.79M | 3.37M | Total Assets |
| 5.30M | 5.57M | 7.73M | 10.65M | 9.05M | 6.91M | Total Debt |
| 2.01M | 2.70M | 4.01M | 4.00M | 1.69M | 2.19M | Net Debt |
| -1.67M | -635.10K | -775.65K | -4.66M | -4.10M | -1.18M | Total Liabilities |
| 2.88M | 3.54M | 5.82M | 5.27M | 2.66M | 3.21M | Stockholders Equity |
| 2.42M | 2.03M | 1.91M | 5.38M | 6.39M | 3.70M |
| Cash Flow | Free Cash Flow | ||||
| -3.94M | -5.32M | -5.13M | -4.11M | -4.78M | -5.89M | Operating Cash Flow |
| -3.94M | -5.26M | -5.13M | -4.09M | -4.78M | -5.89M | Investing Cash Flow |
| 0.00 | -62.40K | -2.13K | -25.23K | -2.12K | -2.38K | Financing Cash Flow |
| 1.88M | 3.67M | 1.27M | 7.02M | 7.19M | 3.70M |
AdAlta Ltd. Peers Comparison
AdAlta Ltd. Corporate Events
AdAlta Limited has released an investor presentation highlighting its focus on commercializing cellular immunotherapies. The company emphasizes the inherent risks associated with investment in its projects, including the uncertainty of regulatory approvals and commercial success. Stakeholders are advised to consider these risks and consult with investment advisors as needed.
AdAlta Limited has announced the commencement of rights trading on the ASX under the code 1ADR as part of a renounceable rights issue. This offer aims to raise approximately $1.29 million by issuing new shares and options to eligible shareholders, with the proceeds intended to support the company’s ongoing operations and strategic initiatives. The rights trading period will end on May 21, 2025. This move is expected to bolster AdAlta’s financial position, enabling further investment in their innovative cellular immunotherapy projects, thereby enhancing their market positioning in the high-growth segment of solid cancer treatments.
AdAlta Ltd. has announced an update to the terms of a proposed issue of securities, specifically options with an exercise price of 1.0 cent expiring on June 3, 2028. This update, which is part of a standard pro rata issue, involves rounding up fractional entitlements for eligible shareholders to the nearest whole number. The issue date for these securities is set for June 4, 2025. This move is expected to enhance AdAlta’s financial flexibility and potentially increase shareholder value, reflecting the company’s strategic efforts to strengthen its market position.
AdAlta Ltd. has announced a renounceable pro rata rights offer to its shareholders in Australia and New Zealand, allowing them to purchase new ordinary shares and options. This offer is expected to raise approximately $1.29 million, increasing the company’s total issued shares significantly. The directors of AdAlta have committed to taking up their entitlements in full, and the offer is structured to exclude foreign shareholders due to regulatory and cost considerations. The proceeds from the sale of rights for ineligible shareholders will be managed by Mahe Capital Pty Ltd.
AdAlta Ltd. has announced a renounceable pro rata rights offer to its shareholders in Australia and New Zealand, allowing them to acquire new shares and options. This initiative aims to raise approximately $1.29 million, which will be used to advance business development transactions, evaluate strategic options, and support general working capital. The offer is expected to increase AdAlta’s total issued shares significantly, potentially impacting its market positioning by providing additional funds for its strategic initiatives.
AdAlta Limited has announced a target market determination for its Attaching Options, which are being offered to eligible shareholders as part of a prospectus dated May 1, 2025. These options allow shareholders to acquire additional shares in the company, providing potential for increased investment and exposure to the company’s future operations. The options are aimed at investors with a medium to long-term outlook, who are financially prepared to exercise the options or trade them before the expiry date in 2028. However, the investment is considered highly speculative, with no income guarantee or capital protection, making it suitable only for investors who can bear potential losses.
AdAlta Ltd. has announced an update to its proposed issue of securities, specifically revising the terms outlined in a previous prospectus. The update includes details about option securities with an exercise price of 1.0 cent, set to expire on June 3, 2028. This move is part of a standard pro rata issue, which is renounceable, and aims to align with the company’s strategic financial planning. The update is expected to impact AdAlta’s market operations by potentially increasing liquidity and providing additional capital for its ongoing projects.
AdAlta Limited has announced a pro rata, renounceable offer to raise approximately $1.29 million by issuing two new shares for every three shares held by eligible shareholders at a price of 0.3 cents per new share. This capital raising effort includes the issuance of one new option for every two new shares subscribed, which is aimed at strengthening the company’s financial position and supporting its ongoing operations.
AdAlta Limited has announced a change in its registered office and business address to Suite 201, 697 Burke Road, Camberwell, VIC 3124, Australia. This move is part of the company’s ongoing efforts to enhance its operations and strategic positioning in the biotechnology industry, particularly in the rapidly growing cellular immunotherapy market. With a focus on solid tumors, AdAlta aims to leverage its innovative approaches and partnerships to capture a significant share of this expanding market, which is projected to reach US$20.3 billion by 2028.
AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, offering new shares at a 51% discount to the 15-day VWAP. The funds will support the company’s business development and strategic evaluations, enhancing its positioning in the biotechnology sector. The rights issue is partially underwritten and aims to provide shareholders with additional options, reflecting AdAlta’s commitment to unlocking shareholder value.
AdAlta Limited has made significant progress in its ‘East to West’ cellular immunotherapy strategy, executing three CAR-T term sheets and completing substantial technical due diligence. Despite a challenging financing environment, the company is working to secure funding and partnerships, including a Heads of Agreement with SYNthesis BioVentures for seed funding. AdAlta has ceased internal R&D activities to focus resources on strategic transactions and cost management, aiming to enhance shareholder value through external partnerships and funding.
AdAlta Ltd. has requested a trading halt on the Australian Securities Exchange as it evaluates new financing opportunities. This move is intended to help the company manage its disclosure obligations and maintain an orderly market for its shares, with trading expected to resume by May 2, 2025, or upon the release of a relevant announcement.
AdAlta Ltd. has announced the issuance of 900,000 unquoted equity securities as part of an employee incentive scheme. This move is aimed at enhancing employee engagement and aligning their interests with the company’s growth objectives, potentially strengthening AdAlta’s position in the competitive biotechnology sector.
AdAlta Limited has secured its first external investment for its ‘East to West’ cellular immunotherapy strategy through a seed financing agreement with SYNthesis BioVentures. This investment will accelerate the development and licensing of three cellular immunotherapy assets, positioning AdAlta to bring Asian innovations to Western markets. The agreement signifies a vote of confidence in AdAlta’s strategy and is expected to enhance the company’s market positioning and operational capabilities.
AdAlta Limited has issued 11,111,111 fully paid ordinary shares as part of its funding arrangements with NLSC, LLC. This share issuance, priced at $0.009 per share, is intended to partially settle an outstanding subscription amount, reflecting the company’s ongoing efforts to manage its financial commitments and support its operational growth.
AdAlta Limited announced its participation in the Stocks on Track event in Sydney, where CEO Dr. Tim Oldham will present the company’s ‘East to West’ cellular immunotherapy strategy and discuss the partnering strategy for its AD-214 product. This presentation underscores AdAlta’s focus on improving outcomes for solid cancer patients and its strategic positioning in the high-growth cellular immunotherapy market. The company’s approach involves in-licensing products from Asia, establishing US FDA-regulated manufacturing, and conducting clinical studies to position products for further commercialization.
AdAlta Limited has received a $424,600 advance on its FY25 R&D Tax Incentive rebate through a loan facility with Radium Capital. This funding will support the company’s due diligence and negotiation efforts for three cellular immunotherapy products under its ‘East to West’ strategy, aimed at addressing the underserved market of solid cancer treatments. The advance will facilitate the progression of these products, which are the first to emerge from this strategy, potentially strengthening AdAlta’s position in the rapidly growing cellular immunotherapy sector.
AdAlta Limited announced its participation in the 4th BioCentury-BayHelix East-West Biopharma Summit in Singapore, where CEO Dr. Tim Oldham will present the company’s ‘East to West’ cellular immunotherapy strategy. This opportunity aligns with AdAlta’s goal to globalize Asian innovation in cellular immunotherapies, potentially enhancing its industry positioning and stakeholder value. The summit provides a platform for AdAlta to showcase its innovative approach and strategic integration of Asian and Western biopharma strengths, potentially attracting interest from larger biopharmaceutical companies for future collaborations.
AdAlta Ltd. has announced the issuance of 150,395 fully paid ordinary shares following the exercise of Performance Rights by employees as part of the Omnibus Equity Plan. This move reflects the company’s compliance with relevant legal frameworks and underscores its commitment to rewarding employee contributions, potentially strengthening its market position and stakeholder relations.
AdAlta Limited reported a significant decline in revenues by 67.1% for the half-year ending December 31, 2024, totaling $375,086. The company’s loss after tax reduced by 14.5% compared to the previous year, amounting to $2,576,431. Despite the financial challenges, no dividends were declared during this period. This financial report highlights a challenging period for AdAlta Limited, reflecting the broader difficulties in the biopharmaceutical industry, which may impact investor confidence.